Data / Drug companies / Glaxo Wellcome Manufacturing Pte. Ltd
Glaxo Wellcome Manufacturing Pte. Ltd: 13 products in the FDA NDC directory, labeler code 52482
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Glaxo Wellcome Manufacturing Pte. Ltd (labeler code 52482) lists 13 products in the FDA National Drug Code Directory. By type: 13 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on February 1, 2023.
The request: Watch Glaxo Wellcome Manufacturing Pte. Ltd (FDA labeler code 52482): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 52482
- Products in commercial distribution
- 13
- Packages
- 13
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- February 26, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 13 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 13 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 13 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Daprodustat | 52482-020 | Powder | Bulk ingredients | February 1, 2023 |
| Ondansetron | 52482-019 | Powder | Bulk ingredients | December 31, 2019 |
| Cabotegravir sodium | 52482-018 | Powder | Bulk ingredients | December 23, 2019 |
| Cabotegravir | 52482-017 | Powder | Bulk ingredients | December 23, 2019 |
| Dolutegravir sodium | 52482-016 | Powder | Bulk ingredients | February 19, 2018 |
| Trametinib | 52482-014 | Powder | Bulk ingredients | September 2, 2014 |
| Umeclidinium bromide | 52482-012 | Powder | Bulk ingredients | August 25, 2014 |
| Naratriptan hydrochloride | 52482-011 | Powder | Bulk ingredients | August 24, 2014 |
| Vilanterol trifenatate | 52482-009 | Powder | Bulk ingredients | June 25, 2014 |
| Fluticasone furoate | 52482-008 | Powder | Bulk ingredients | June 25, 2014 |
| Lamivudine | 52482-003 | Powder | Bulk ingredients | March 13, 2014 |
| Salmeterol xinafoate | 52482-002 | Powder | Bulk ingredients | March 11, 2014 |
| Fluticasone propionate | 52482-001 | Powder | Bulk ingredients | February 26, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.